MINERALYS THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
MINERALYS THERAPEUTICS, INC. (MLYS) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $7.36 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $7.36M, a 61.54% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $6.55M, a 79.64% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $5.84M, a 86.08% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $4.55M, a 58.53% increase year-over-year.
- MINERALYS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $19.32M, a 70.47% increase from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $11.34M, a 124.03% increase from fiscal 2023.
- MINERALYS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $5.06M, a 1012.09% increase from fiscal 2022.
- MINERALYS THERAPEUTICS, INC. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $455.00K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $7.36M 10-Q · filed 2026-08-11 | $13.90M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2026-03-31 | $6.55M 10-Q · filed 2026-08-11 | |||
| 2025-12-31 | $19.32M 10-K · filed 2026-03-12 | |||
| 2025-09-30 | $5.84M 10-Q · filed 2025-11-10 | $10.39M derived: sum of 2 quarters · filed 2026-08-11 | $14.04M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-06-30 | $4.55M 10-Q · filed 2026-08-11 | $8.20M derived: sum of 2 quarters · filed 2026-08-11 | ||
| 2025-03-31 | $3.65M 10-Q · filed 2026-08-11 | |||
| 2024-12-31 | $11.34M 10-K · filed 2026-03-12 | |||
| 2024-09-30 | $3.14M 10-Q · filed 2025-11-10 | $6.01M derived: sum of 2 quarters · filed 2025-11-10 | $8.20M derived: sum of 3 quarters · filed 2025-11-10 | |
| 2024-06-30 | $2.87M 10-Q · filed 2025-11-10 | $5.06M derived: sum of 2 quarters · filed 2025-11-10 | ||
| 2024-03-31 | $2.19M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $5.06M 10-K · filed 2025-02-12 | |||
| 2023-09-30 | $1.58M 10-Q · filed 2024-11-12 | $2.85M derived: sum of 2 quarters · filed 2024-11-12 | $3.60M derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $1.28M 10-Q · filed 2024-11-12 | $2.02M derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $749.00K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $455.00K 10-K · filed 2024-03-21 | |||
| 2022-09-30 | $192.00K 10-Q · filed 2023-11-07 | $218.00K derived: sum of 2 quarters · filed 2023-11-07 | $237.00K derived: sum of 3 quarters · filed 2023-11-07 | |
| 2022-06-30 | $26.00K 10-Q · filed 2023-11-07 | $45.00K derived: sum of 2 quarters · filed 2023-11-07 | ||
| 2022-03-31 | $19.00K 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |